nature portfolio

Corresponding author(s): Maximilian Merz

Last updated by author(s): Mar 10, 2025

Editorial Policy Checklist

This form is used to ensure compliance with Nature Portfolio editorial policies related to research ethics and reproducibility. For further information, please see our editorial policies site. All relevant questions on the form must be answered.

Competing interests

Policy information about competing interests

In the interest of transparency and to help readers form their own judgements of potential bias, Nature Portfolio journals require authors to declare any competing financial and/or non-financial interest in relation to the work described in the submitted manuscript.

Competing interests declaration

☐ We declare that none of the authors have competing financial or non-financial interests as defined by Nature Portfolio.

☒ We declare that one or more of the authors have a competing interest as defined by Nature Portfolio.

MM gave advisory boards and received honoraria and research support from Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks, Sanofi, and Takeda MH gave advisory boards and received honoraria from Abbvie, Beigene, Jazz, Janssen, Stemline Menarini and Takeda, and received research support from EDO-Mundipharma, Janpix, Novartis, and Roche. S.F.: consultant and/or speaker fees from Novartis Pharma, Janssen-Cilag, Vertex Pharmaceuticals (Germany), Kite/Gilead Sciences, MSGO and Bristol-Myers Squibb. U.K.: consultant and/or speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, Miltenyi Biotec and Novartis Pharma and Bristol-Myers Squibb. K.H.M.: BMS (consultancy and honoraria), AbbVie (honoraria, research funding), Pfizer (honoraria), Otsuka (honoraria), Janssen (honoraria) and Novartis (consultancy). U.P.: Syros (consultancy, honoraria, research funding), MDS Foundation (membership on an entity's Board of Directors or advisory committees), Silence Therapeutics (consultancy, honoraria, research funding), Celgene (honoraria), Takeda (consultancy, honoraria, research funding), Fibrogen (research funding), Servier (consultancy, honoraria, research funding), Roche (research funding), Merck (research funding), Amgen (consultancy, research funding), Novartis (consultancy, honoraria, research funding), AbbVie (consultancy), Curis (consultancy, research funding), Janssen Biotech (consultancy, research funding), Jazz (consultancy, honoraria, research funding), BeiGene (research funding), Geron (consultancy, research funding) and Bristol-Myers Squibb (consultancy, honoraria, membership on an entity's Board of Directors or advisory committees, other, travel support, medical writing support, research funding). M.J.: Novartis (honoraria), Amgen (honoraria), Pfizer (honoraria), Blueprint Medicine (honoraria), BMS (honoraria) and Jazz (honoraria). L. C. H has received funding for clinical trials from Alexion, Amolyte, and Ascendis to his institution, and honoraria from Ascendis, Amgen, and UCB for consultancies and adboards to himself. VV gave advisory boards for Janssen Cilag, BMS Celgene, MSD, Novartis, Sobi, Caribou and received honoraria from Novartis, Gilead Kite, BMS Celgene, Janssen Cilag, Sobi, Amgen, Abbvie, Takeda. All other authors declare no competing interests.

Authorship

Policy information about authorship

Prior to submission all listed authors must agree to all manuscript contents, the author list and its order and the author contribution statements. Any changes to the author list after submission must be approved by all authors.

☒ We have read the Nature Portfolio Authorship Policy and confirm that this manuscript complies.

Large Language Models (LLMs), such as ChatGPT, do not currently satisfy our authorship criteria. Notably an attribution of authorship carries with it accountability for the work, which cannot be effectively applied to LLMs. Use of an LLM should be properly documented in the Methods section (and if a Methods section is not available, in a suitable alternative part) of the manuscript.

☒ We confirm that the author list of this manuscript does not include any Large Language Models (LLMs).

Policy information about Authorship: inclusion & ethics in global research

All authors are encouraged to provide an "Inclusion & Ethics" statement where relevant.

☒ We have provided an "Inclusion & Ethics" statement.

Data availability

Policy information about availability of data

Data availability statement

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

☒ We have provided a full data availability statement in the manuscript.

Mandated accession codes (where applicable)

Confirm that all relevant data are deposited into a public repository and that accession codes are provided.

☐ All relevant accession codes are provided ☒ Accession codes will be available before publication ☐ No data with mandated deposition

Code availability

Policy information about availability of computer code

Code availability statement

For all studies using custom code or mathematical algorithm that is deemed central to the conclusions, the manuscript must include a statement under the heading "Code availability" describing how readers can access the code, including any access restrictions. Code availability statements should be provided as a separate section after the data availability statement but before the References.

☒ We have provided a full code availability statement in the manuscript

Data presentation

For all data presented in a plot, chart or other visual representation confirm that:

n/a	Confirmed
☐	☒ Individual data points are shown when possible, and always for $n \leq 10$
☐	☒ The format shows data distribution clearly (e.g. dot plots, box-and-whisker plots)
☐	☒ Box-plot elements are defined (e.g. center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers)
☐	☒ Clearly defined error bars are present and what they represent (SD, SE, CI) is noted

Image integrity

Policy information about image integrity

☒ We have read Nature Portfolio's image integrity policy and all images comply.

Unprocessed data must be provided upon request. Please double-check figure assembly to ensure that all panels are accurate (e.g. all labels are correct, no inadvertent duplications have occurred during preparation, etc.).

Where blots and gels are presented, please take particular care to ensure that lanes have not been spliced together, that loading controls are run on the same blot, and that unprocessed scans match the corresponding figures.

Additional policy considerations

Some types of research require additional policy disclosures. Please indicate whether each of these apply to your study. If you are not certain, please read the appropriate section before selecting a response.

Does not apply	Involved in the study
☒	☐ Macromolecular structural data
☒	☐ Unique biological materials
☒	☐ Research animals and/or animal-derived materials that require ethical approval
☒	☐ Human embryos, gametes and/or stem cells
☐	☒ Human research participants
☐	☒ Clinical data
☒	☐ Archaeological, geological, and palaeontological materials

Human research participants

Policy information about studies involving human research participants

Ethical compliance

☒ We have complied with all relevant ethical regulations and include a statement affirming this in the manuscript.

Ethics committee

Confirm that the manuscript states the name(s) of the board and/or institution that:

☒ Approved the study protocol -OR- ☐ Provided guidelines for study procedures (if protocol approval is not required)

Informed consent

☒ We have obtained informed consent from all participants and this is noted in the manuscript.

Identifiable images

For publication of identifiable images of research participants, confirm that consent to publish was obtained and is noted in the Methods.

Authors must ensure that consent meets the conditions set out in the Nature Portfolio participant release form.

☐ Yes ☒ No identifiable images of human research participants

Clinical studies

Policy information about clinical studies

Clinical trial registration

☐ We have provided the trial registration number from ClinicalTrials.gov or an equivalent agency in the manuscript.

Phase 2 and 3 randomized controlled trials

We have provided the CONSORT checklist with your submission.

☐ Yes ☐ No ☒ Not a phase 2/3 randomized controlled trial

Tumor marker prognostic studies

We have followed the REMARK reporting guidelines.

☐ Yes ☐ No ☒ Not a tumor marker prognostic study

I certify that all the above information is complete and correct.

Typed signature Maximilian Merz Date Mar 9, 2025